Amanat Acquisition agrees to combine with obesity drug developer Corxel US

• Amanat Acquisition agreed to combine with Corxel US, creating a publicly listed company focused on oral obesity treatments.
• The transaction is expected to close in the first half of 2027, with Corxel US becoming a wholly owned subsidiary.
• Expected gross proceeds total approximately $377 million, including a $300 million PIPE, before transaction costs and assuming no shareholder redemptions.
• Proceeds are expected to fund operations through 2029, including global Phase 3 development of oral obesity drug CX11.
• The deal excludes other Corxel Group assets, including Corxel HK and its JX10 stroke program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amanat Acquisition Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260600PRIMZONEFULLFEED9852724) on October 26, 2026, and is solely responsible for the information contained therein.